AR106987A1 - Compuestos de diamina-arilsulfonamida sustituidos con hidroxialquilamina e hidroxicicloalquilamina con actividad selectiva en canales de sodio activados por voltaje - Google Patents
Compuestos de diamina-arilsulfonamida sustituidos con hidroxialquilamina e hidroxicicloalquilamina con actividad selectiva en canales de sodio activados por voltajeInfo
- Publication number
- AR106987A1 AR106987A1 ARP160103829A ARP160103829A AR106987A1 AR 106987 A1 AR106987 A1 AR 106987A1 AR P160103829 A ARP160103829 A AR P160103829A AR P160103829 A ARP160103829 A AR P160103829A AR 106987 A1 AR106987 A1 AR 106987A1
- Authority
- AR
- Argentina
- Prior art keywords
- carbon atoms
- branched
- linear
- cyclic alkyl
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Un compuesto, o una sal farmacéuticamente aceptable del mismo, que tiene la estructura de fórmula (1), en la que: R¹ es: -Cl, -Br, o alquilo lineal, ramificado o cíclico de hasta 3 átomos de carbono; R² es: (a) un resto de la fórmula (2), en la que, uno de R³ᵃ y R³ᵇ es -H y el otro es -H, -F, CH₃; o (b) un resto de la fórmula (3); y E es: (I) un resto de fórmula (4), en la que: R⁶ es -H o un alquilo lineal, ramificado o cíclico de hasta 6 átomos de carbono; y B es: (a) un resto de la fórmula (5), resto que se une a nitrógeno en uno de R⁷A, R⁷B, o R⁷C por medio de -CH₂-, o se une a nitrógeno directamente en uno de R⁷C, y en la que: m es 0, 1 ó 2; R⁷A y R⁷B son independientemente para cada aparición -H, o un alquilo lineal, ramificado o cíclico de hasta 3 átomos de carbono cuando no se selecciona para unirse al nitrógeno por medio de metileno; R⁷C cuando no se selecciona para unirse al nitrógeno directamente o por medio de metileno es independientemente para cada aparición (i) -H; (ii) alquilo lineal, ramificado o cíclico de hasta tres carbonos; y R⁷D es: (ai) -H; o (aii) un alquilo lineal, ramificado o cíclico de hasta 5 átomos de carbono; o (b) un resto de la fórmula (6), en la que: R⁷ʰ es -H o un alquilo lineal, ramificado o cíclico de hasta 3 átomos de carbono; y R⁷ᵍ y R⁷ᶠ se seleccionan como sigue: (i) R⁷ᵍ es un alquilo lineal de al menos 2, hasta 4 átomos de carbono, un alquilo ramificado de al menos 3 hasta 6 átomos de carbono o alquilo cíclico de hasta 6 átomos de carbono y R⁷ᶠ es un alquilo lineal de al menos 2 átomos de carbono hasta 4 átomos de carbono, o un alquilo ramificado o cíclico de hasta 6 átomos de carbono que está sustituido con -OH en un átomo de carbono del mismo que está unido en beta, o más lejos, al nitrógeno al que está unido; o (ii) R⁷ᶠ es -H o un alquilo lineal, ramificado o cíclico de hasta 6 átomos de carbono o y R⁷ᵍ es -(CH₂)₁₋₂-(HC(OH))-(CH₂)₁₋₂; (II) un resto de fórmula (7), en la que cada R⁸ es independientemente -H o alquilo lineal, ramificado o cíclico de hasta 6 átomos de carbono; o (III) un resto de fórmula (8), en la que: R⁹A es independientemente para cada aparición (i) -H; (ii) -OH; o (iii) un alquilo lineal, ramificado o cíclico de hasta 6 átomos de carbono que está opcionalmente sustituido en un átomo de carbono del mismo con un -OH; R¹⁰A es independientemente para cada aparición (i) -H; o (ii) alquilo lineal, ramificado o cíclico de hasta 6 átomos de carbono que está opcionalmente sustituido en un átomo de carbono del mismo con un -OH; R¹¹A es -H o un, alquilo de 2 ó 3 carbonos que está opcionalmente sustituido en un carbono b o g con un -OH, con la condición de que únicamente un sustituyente -OH esté presente entre todos de R⁹A, R¹⁰A y R¹¹A.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562269327P | 2015-12-18 | 2015-12-18 | |
| US201662290235P | 2016-02-02 | 2016-02-02 | |
| US201662420956P | 2016-11-11 | 2016-11-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR106987A1 true AR106987A1 (es) | 2018-03-07 |
Family
ID=57708830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103829A AR106987A1 (es) | 2015-12-18 | 2016-12-14 | Compuestos de diamina-arilsulfonamida sustituidos con hidroxialquilamina e hidroxicicloalquilamina con actividad selectiva en canales de sodio activados por voltaje |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US10221167B2 (es) |
| EP (1) | EP3390374B1 (es) |
| JP (1) | JP6572392B2 (es) |
| KR (1) | KR20180095598A (es) |
| CN (1) | CN108699015A (es) |
| AR (1) | AR106987A1 (es) |
| AU (1) | AU2016370554B2 (es) |
| BR (1) | BR112018012327A2 (es) |
| CA (1) | CA3008611A1 (es) |
| CL (1) | CL2018001640A1 (es) |
| CO (1) | CO2018006137A2 (es) |
| CR (1) | CR20180322A (es) |
| DO (1) | DOP2018000150A (es) |
| EA (1) | EA201891313A1 (es) |
| EC (1) | ECSP18052850A (es) |
| HK (1) | HK1255027A1 (es) |
| IL (1) | IL260052A (es) |
| MX (1) | MX2018007450A (es) |
| NI (1) | NI201800067A (es) |
| PE (1) | PE20181495A1 (es) |
| PH (1) | PH12018501288A1 (es) |
| SG (1) | SG11201804936UA (es) |
| SV (1) | SV2018005708A (es) |
| TN (1) | TN2018000195A1 (es) |
| TW (1) | TW201726637A (es) |
| WO (1) | WO2017106226A1 (es) |
| ZA (1) | ZA201803591B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016370677A1 (en) * | 2015-12-18 | 2018-06-07 | Merck Sharp & Dohme Corp. | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| JP6572392B2 (ja) * | 2015-12-18 | 2019-09-11 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 電位作動型ナトリウムチャネルにおいて選択的活性を有する、ヒドロキシアルキルアミンおよびヒドロキシシクロアルキルアミンで置換されたジアミン−アリールスルホンアミド化合物 |
| TWI773657B (zh) | 2015-12-18 | 2022-08-11 | 美商亞德利克斯公司 | 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物 |
| JP2019532077A (ja) | 2016-10-17 | 2019-11-07 | ジェネンテック， インコーポレイテッド | 治療用化合物及びその使用方法 |
| MA46615A (fr) * | 2016-10-27 | 2019-09-04 | Bristol Myers Squibb Co | Inhibiteurs de nav1.7 de type acyl-sulfonamide |
| WO2018093694A1 (en) * | 2016-11-17 | 2018-05-24 | Merck Sharp & Dohme Corp. | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| CN110546148A (zh) | 2017-03-24 | 2019-12-06 | 基因泰克公司 | 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物 |
| TW202000651A (zh) | 2018-02-26 | 2020-01-01 | 美商建南德克公司 | 治療性組成物及其使用方法 |
| US10947251B2 (en) | 2018-03-30 | 2021-03-16 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| CR20210099A (es) | 2018-08-31 | 2021-06-24 | Xenon Pharmaceuticals Inc | Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapèuticos |
| CN111285825B (zh) * | 2018-12-10 | 2023-02-17 | 中国科学院上海药物研究所 | 一类苯磺酰胺取代的衍生物，其制法及其用途 |
| WO2020248123A1 (en) * | 2019-06-11 | 2020-12-17 | Merck Sharp & Dohme Corp. | Hydroxypyrrolidine-substituted arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| CN113527281B (zh) * | 2020-04-20 | 2023-12-22 | 昆山彭济凯丰生物科技有限公司 | 杂环化合物及其制备方法和应用 |
| CN117362206B (zh) * | 2023-12-08 | 2024-02-20 | 四川大学华西第二医院 | 一类芳基磺酰胺类化合物、合成方法及用途 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1451160B1 (en) | 2001-11-01 | 2010-01-13 | Icagen, Inc. | Pyrazole-amides for use in the treatment of pain |
| US7244744B2 (en) | 2001-11-01 | 2007-07-17 | Icagen, Inc. | Piperidines |
| US9278088B2 (en) | 2002-02-19 | 2016-03-08 | Xenon Pharmaceuticals Inc. | Methods for identifying analgesic agents |
| TW200524888A (en) * | 2003-08-08 | 2005-08-01 | Vertex Pharma | Compositions useful as inhibitors of voltage-gated ion channels |
| AR056968A1 (es) | 2005-04-11 | 2007-11-07 | Xenon Pharmaceuticals Inc | Compuestos espiro-oxindol y composiciones farmacéuticas |
| TW200833695A (en) | 2006-10-12 | 2008-08-16 | Xenon Pharmaceuticals Inc | Use of spiro-oxindole compounds as therapeutic agents |
| WO2009012242A2 (en) * | 2007-07-13 | 2009-01-22 | Icagen, Inc. | Sodium channel inhibitors |
| WO2009012241A1 (en) | 2007-07-13 | 2009-01-22 | Icagen, Inc. | Sodium channel inhibitors |
| RU2011119626A (ru) | 2008-10-17 | 2012-11-27 | Ксенон Фармасьютикалз Инк. | Спирооксиндольные соединения и их применение в качестве терапевтичеких средств |
| JP5053459B2 (ja) | 2009-01-12 | 2012-10-17 | アイカジェン， インコーポレイテッド | スルホンアミド誘導体 |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| EP2488531B1 (en) | 2009-10-14 | 2014-03-26 | Xenon Pharmaceuticals Inc. | Synthetic methods for spiro-oxindole compounds |
| WO2011106729A2 (en) | 2010-02-26 | 2011-09-01 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
| EP2590951B1 (en) | 2010-07-09 | 2015-01-07 | Pfizer Limited | Benzenesulfonamides useful as sodium channel inhibitors |
| ES2532356T3 (es) | 2010-07-09 | 2015-03-26 | Pfizer Limited | N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje |
| US9096558B2 (en) | 2010-07-09 | 2015-08-04 | Pfizer Limited | N-sulfonylbenzamide compounds |
| US8592692B2 (en) | 2011-07-22 | 2013-11-26 | Tyco Electronics Corporation | Substrate having a plural diameter via |
| AU2012296529A1 (en) | 2011-08-17 | 2014-02-20 | Amgen Inc. | Heteroaryl sodium channel inhibitors |
| RU2014121489A (ru) | 2011-10-28 | 2015-12-10 | Мерк Шарп И Доум Корп. | Соединения бензоксазолинона с селективной активностью в отношении потенциалзависимых натриевых каналов |
| US9481677B2 (en) | 2011-10-31 | 2016-11-01 | Xenon Pharmaceuticals Inc. | Biaryl ether sulfonamides and their use as therapeutic agents |
| WO2013064983A1 (en) | 2011-10-31 | 2013-05-10 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| EP2788332A1 (en) | 2011-12-07 | 2014-10-15 | Amgen, Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
| WO2013102826A1 (en) | 2012-01-04 | 2013-07-11 | Pfizer Limited | N-aminosulfonyl benzamides |
| WO2013134518A1 (en) | 2012-03-09 | 2013-09-12 | Amgen Inc. | Sulfamide sodium channel inhibitors |
| AR091112A1 (es) | 2012-05-22 | 2015-01-14 | Genentech Inc | Benzamidas n-sustituidas como inhibidores de los canales de sodio nav1.7 |
| EP2870138B1 (en) | 2012-07-06 | 2018-08-22 | Genentech, Inc. | N-substituted benzamides and methods of use thereof |
| CA2887845C (en) | 2012-10-15 | 2020-12-15 | Daewoong Pharmaceutical Co., Ltd. | Sodium channel blockers, preparation method thereof and use thereof |
| US9388179B2 (en) | 2012-10-26 | 2016-07-12 | Merck Sharp & Dohme Corp. | N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels |
| KR20150074122A (ko) | 2012-10-26 | 2015-07-01 | 머크 샤프 앤드 돔 코포레이션 | 전압-게이팅 나트륨 채널에서 선택적 활성을 갖는 벤족사졸리논 화합물 |
| JP2014101287A (ja) | 2012-11-16 | 2014-06-05 | Daiichi Sankyo Co Ltd | インドール誘導体 |
| KR20150131233A (ko) | 2013-03-14 | 2015-11-24 | 제넨테크, 인크. | 치환된 트리아졸로피리딘 및 이의 사용 방법 |
| JP6227112B2 (ja) | 2013-03-15 | 2017-11-08 | ジェネンテック， インコーポレイテッド | 置換ベンゾオキサゾールとその使用方法 |
| RU2669367C2 (ru) | 2013-03-15 | 2018-10-11 | Хромоселл Корпорейшн | Модуляторы натриевого канала для лечения боли |
| US9212182B2 (en) | 2013-06-12 | 2015-12-15 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
| KR102306951B1 (ko) | 2013-07-10 | 2021-10-01 | 버텍스 파마슈티칼스 인코포레이티드 | 이온 채널의 조절제로서의 융합된 피페리딘 아미드 |
| CN103389108B (zh) * | 2013-07-30 | 2016-02-24 | 邢皓宇 | 一种电子计步器 |
| MY181928A (en) | 2013-09-10 | 2021-01-14 | Chromocell Corp | Sodium channel modulators for the treatment of pain and diabetes |
| US9663508B2 (en) | 2013-10-01 | 2017-05-30 | Amgen Inc. | Biaryl acyl-sulfonamide compounds as sodium channel inhibitors |
| EP3074377B1 (en) | 2013-11-27 | 2018-10-17 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| WO2015077905A1 (en) * | 2013-11-29 | 2015-06-04 | Merck Sharp & Dohme Corp. | Bicycloamine-substituted-n-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels |
| EP3126360A1 (en) | 2014-03-29 | 2017-02-08 | Lupin Limited | Sulfonamide compounds as voltage gated sodium channel modulators |
| US10005724B2 (en) | 2014-07-07 | 2018-06-26 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| JP6572392B2 (ja) * | 2015-12-18 | 2019-09-11 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 電位作動型ナトリウムチャネルにおいて選択的活性を有する、ヒドロキシアルキルアミンおよびヒドロキシシクロアルキルアミンで置換されたジアミン−アリールスルホンアミド化合物 |
| AU2016370677A1 (en) | 2015-12-18 | 2018-06-07 | Merck Sharp & Dohme Corp. | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| US10442778B2 (en) | 2016-03-22 | 2019-10-15 | Merck Sharp & Dohme Corp. | N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channels |
| WO2018093694A1 (en) | 2016-11-17 | 2018-05-24 | Merck Sharp & Dohme Corp. | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
-
2016
- 2016-12-14 JP JP2018531094A patent/JP6572392B2/ja not_active Expired - Fee Related
- 2016-12-14 CA CA3008611A patent/CA3008611A1/en not_active Abandoned
- 2016-12-14 EA EA201891313A patent/EA201891313A1/ru unknown
- 2016-12-14 KR KR1020187020090A patent/KR20180095598A/ko active IP Right Grant
- 2016-12-14 SG SG11201804936UA patent/SG11201804936UA/en unknown
- 2016-12-14 TN TNP/2018/000195A patent/TN2018000195A1/en unknown
- 2016-12-14 BR BR112018012327A patent/BR112018012327A2/pt not_active Application Discontinuation
- 2016-12-14 PE PE2018001100A patent/PE20181495A1/es unknown
- 2016-12-14 MX MX2018007450A patent/MX2018007450A/es unknown
- 2016-12-14 CR CR20180322A patent/CR20180322A/es unknown
- 2016-12-14 CN CN201680081234.0A patent/CN108699015A/zh active Pending
- 2016-12-14 TW TW105141337A patent/TW201726637A/zh unknown
- 2016-12-14 US US15/378,465 patent/US10221167B2/en active Active
- 2016-12-14 AR ARP160103829A patent/AR106987A1/es unknown
- 2016-12-14 AU AU2016370554A patent/AU2016370554B2/en not_active Ceased
- 2016-12-14 WO PCT/US2016/066445 patent/WO2017106226A1/en active Application Filing
- 2016-12-14 EP EP16820497.2A patent/EP3390374B1/en active Active
-
2018
- 2018-05-30 ZA ZA2018/03591A patent/ZA201803591B/en unknown
- 2018-06-12 NI NI201800067A patent/NI201800067A/es unknown
- 2018-06-13 SV SV2018005708A patent/SV2018005708A/es unknown
- 2018-06-14 PH PH12018501288A patent/PH12018501288A1/en unknown
- 2018-06-14 IL IL260052A patent/IL260052A/en unknown
- 2018-06-15 CL CL2018001640A patent/CL2018001640A1/es unknown
- 2018-06-15 CO CONC2018/0006137A patent/CO2018006137A2/es unknown
- 2018-06-18 DO DO2018000150A patent/DOP2018000150A/es unknown
- 2018-07-12 EC ECSENADI201852850A patent/ECSP18052850A/es unknown
- 2018-11-06 HK HK18114148.2A patent/HK1255027A1/zh unknown
-
2019
- 2019-01-11 US US16/246,068 patent/US20190233406A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20190233406A1 (en) | 2019-08-01 |
| PE20181495A1 (es) | 2018-09-18 |
| JP2019502681A (ja) | 2019-01-31 |
| AU2016370554B2 (en) | 2018-11-29 |
| WO2017106226A1 (en) | 2017-06-22 |
| TW201726637A (zh) | 2017-08-01 |
| US10221167B2 (en) | 2019-03-05 |
| HK1255027A1 (zh) | 2019-08-02 |
| KR20180095598A (ko) | 2018-08-27 |
| CR20180322A (es) | 2018-08-21 |
| EA201891313A1 (ru) | 2018-11-30 |
| JP6572392B2 (ja) | 2019-09-11 |
| ZA201803591B (en) | 2019-04-24 |
| US20170174674A1 (en) | 2017-06-22 |
| CL2018001640A1 (es) | 2018-08-03 |
| BR112018012327A2 (pt) | 2018-12-04 |
| IL260052A (en) | 2018-07-31 |
| MX2018007450A (es) | 2018-11-14 |
| CA3008611A1 (en) | 2017-06-22 |
| TN2018000195A1 (en) | 2019-10-04 |
| PH12018501288A1 (en) | 2019-01-28 |
| CN108699015A (zh) | 2018-10-23 |
| DOP2018000150A (es) | 2018-07-31 |
| EP3390374A1 (en) | 2018-10-24 |
| CO2018006137A2 (es) | 2018-07-10 |
| SG11201804936UA (en) | 2018-07-30 |
| SV2018005708A (es) | 2018-12-14 |
| NI201800067A (es) | 2018-07-24 |
| AU2016370554A1 (en) | 2018-06-14 |
| EP3390374B1 (en) | 2020-08-26 |
| ECSP18052850A (es) | 2018-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR106987A1 (es) | Compuestos de diamina-arilsulfonamida sustituidos con hidroxialquilamina e hidroxicicloalquilamina con actividad selectiva en canales de sodio activados por voltaje | |
| AR106942A2 (es) | Compuestos de isoindolina y composiciones farmacéuticas de los mismos | |
| CO6321166A2 (es) | Compuestos de pirrol | |
| AR105389A1 (es) | Compuestos basados en ferroceno y catalizadores de paladio basados en los mismos para la alcoxicarbonilación de compuestos etilénicamente instaurados | |
| CU24309B1 (es) | Compuestos derivados tienopirimidina y composiciones farmacéuticas que los contienen | |
| AR100233A1 (es) | Composición de limpieza | |
| AR089004A1 (es) | Composiciones farmaceuticas inyectables, metodo, uso | |
| MX2015012411A (es) | Sales de aminas cuaternarias ambientalmente amigables y su uso como estabilizadores de arcilla temporales y/o permanentes y métodos para elaborarlas y utilizarlas. | |
| AR102799A1 (es) | Profármacos de agonistas fenólicos de trpv1 | |
| TR201911139T4 (tr) | Sitotoksik ve anti-mitotik bileşikler ve bunları kullanmanın yöntemleri. | |
| UY35300A (es) | Formulación de combinación de dos compuestos antivirales | |
| CL2016001283A1 (es) | Derivado de urea o sal farmacológicamente aceptable del mismo | |
| TR201906354T4 (tr) | Bi̇r hareketli̇ mobi̇lya parçasi i̇çi̇n tahri̇k ci̇hazi | |
| BR112015031831A2 (pt) | composição de nucleação e composição polimérica termoplástica compreendendo tal composição de nucleação | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| CO2018014018A2 (es) | Método para producir derivado de difenilmetano | |
| CR11266A (es) | Derivados de pirrolidin-2ona como moduladores del receptor de androgeno | |
| CR20140135A (es) | Nuevos derivados de aril-quinolina | |
| AR095549A1 (es) | Composiciones aglutinantes y métodos para su elaboración y uso | |
| AR099646A1 (es) | Fotoestabilizantes de aminas impedidas | |
| AR095097A1 (es) | Compuestos de fenoxietoxi | |
| CY1125355T1 (el) | Πεντακυκλικη ενωση | |
| AR089753A1 (es) | Derivados de amida heterociclicos como antagonistas del receptor p2x7 | |
| CR20160070A (es) | Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos | |
| CY1119111T1 (el) | Trpv1 ανταγωνιστες συμπεριλαμβανομενου διυδροξυ υποκαταστατη και χρησεις αυτων |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |